

## CLAIMS

- June 11

13. Transgenic non-human animal comprising a vector comprising the entire APP gene corresponding to NCBI database, accession no XM\_009710, comprising the Arctic mutation, i.e. nucleotide no. 2225 i mutated from A to G, leading to an amino acid substitution from Glutamic acid to Glycine.

14. Antibodies against the A $\beta$  peptide according to claim 8.

15. A pharmaceutical composition, comprising the peptide according to claim 8 and physiologically acceptable excipients for human and veterinary use.

16. Use of the A $\beta$  peptide according to claim 8 for high throughput screening to find substances with anti-protofibrillar activity.

17. Method for prevention or treatment of AD, comprising the step: decreasing the formation of A $\beta$  protofibrils and/or lower meric forms thereof in a subject having, or suspected of having, AD.

18. A method according to claim 17, wherein said step is by active immunisation with a non wild-type protofibril or compound(s) with protofibril forming ability, wherein said protofibril or compound(s) have enhanced protofibril forming ability and/or enhanced immunogenicity compared to the wild-type counterparts.

19. A method according to claim 17, wherein said step is by passive immunisation with antibodies against a non wild-type protofibril or compound(s) with protofibril forming ability, such as A $\beta$ -Arc.

20. A method according to claim 17, wherein said step is by administration of agents with anti-protofibrillar activity.

21. A method according to claim 17, 18, 19 or 20, in combination with compound(s) having therapeutic benefits to AD patients

sub B1  
Add D4

add  
E5